GlassScriptPhysician profile
Carlos C Say
NPI 1871594085
$1,704.73
in general payments reported to CMS, 2019-2025
19 companies · $141 in 2025
The $141 reported for 2025 was more than what a typical Geriatric Medicine (Family Medicine) provider received nationally (typical 2025 total: $119).
See the full distribution for Geriatric Medicine (Family Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $466 · 2020: $116 · 2021: $69.37 · 2022: $142 · 2023: $156 · 2024: $615 · 2025: $141.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $525 · Food and Beverage: $368 · Education: $19.62.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $525.00 |
| Food and Beverage | $367.60 |
| Education | $19.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $525.00 | 2024 | Enhertu |
| Davol INC. | $184.93 | 2019 | |
| Kite Pharma, INC. | $176.46 | 2020-2023 | Yescarta |
| Bayer Healthcare Pharmaceuticals INC. | $150.70 | 2021-2025 | |
| Lilly USA, LLC | $149.42 | 2022-2025 | Jardiance, Emgality |
| Celgene Corporation | $124.89 | 2019 | |
| Asd Specialty Healthcare, LLC | $72.50 | 2019 | |
| Taiho Oncology, INC. | $65.80 | 2019-2023 | |
| Pfizer INC. | $51.58 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $35.18 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $24.40 | 2020 | |
| Gilead Sciences, INC. | $23.98 | 2019 | |
| Dexcom, INC. | $23.07 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $20.51 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $17.56 | 2019 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $17.36 | 2023 | Ozempic, Rybelsus |
| Tandem Diabetes Care, INC. | $16.73 | 2022 | |
| Akebia Therapeutics INC | $13.51 | 2019 | |
| Covidien LP | $11.15 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carlos Say listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.